NCT06530797View on ClinicalTrials.gov

A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer

Not yet recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DRUG

First-line Adebrelimab regiment for advanced stage ES-SCLC

First-line Adebrelimab in any regiment for advanced stage ES-SCLC

DRUG

Second-line and beyond Adebrelimab regiment for advanced stage ES-SCLC

Second-line and beyond Adebrelimab in any regiment for advanced stage ES-SCLC

All Listed Sponsors
lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06530797 - A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter